chen, chenyan – page 2 – eisai china lnc.-乐鱼官方网站在线登录入口

 chen, chenyan – page 2 – eisai china lnc.-乐鱼官方网站在线登录入口

entries by

eisai and seikagaku enter into agreement for the marketing alliance of si-613, a treatment of osteoarthritis, in south korea

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and seikagaku corporation (headquarters: tokyo, president: ken mizutani, “seikagaku”) announced today that the companies have entered into an agreement for the marketing alliance in south korea for si-613 (diclofenac conjugated sodium hyaluronate), a therapeutic agent for osteoarthritis discovered by seikagaku. eisai and seikagaku signed an agreement for the co-development and marketing alliance in china of si-613 on april 1, 2020. thus, south korea becomes the second country for the companies to conclude the marketing alliance for si-613.

jyseleca® (filgotinib) approved in japan for rheumatoid arthritis

gilead sciences, inc. (nasdaq: gild) and eisai co., ltd. (tokyo, japan) today announced that the japanese ministry of health, labour and welfare (mhlw) has granted gilead k.k. (tokyo, japan) regulatory approval of jyseleca® (filgotinib 200 mg and 100 mg tablets), a once-daily, oral, jak1 preferential inhibitor for the treatment of rheumatoid arthritis (ra) in patients who have had an inadequate response to conventional therapies, including the prevention of structural joint damage.

eisai receives positive opinion from ema’s chmp on use of antiepileptic agent fycompa® in pediatric patients

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced that it has received a positive opinion from the european medicines agency (ema)’s committee for medicinal products for human use (chmp) on the license extension application submitted by its u.k. subsidiary eisai ltd. regarding the use of its in-house discovered and developed anti-epileptic agent (aed) fycompa® (generic name: perampanel) in the treatment of pediatric patients.

new results include findings from the phase 2 leap-004 trial showing an orr of 21.4% in patients with unresectable or advanced melanoma who had previously progressed on an anti-pd-1/pd-l1 therapy

eisai china inc. successfully held “2020 ads summit”

on september 20, 2020, the “2020 ads summit” (ads: advance dementia science) hosted by eisai china inc. was successfully held. featuring the theme of “run into the next decade”, the summit was made up of one main venue (online) and four sub-venues (offline) in beijing, shanghai, guangzhou and chengdu. famous experts from china, japan and south korea and nearly 1,000 guests online and offline made exchanges on the frontier progress of dementia and cognitive disorders.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced that the latest results from the cohort targeting patients with her2-negative breast cancer in the phase i clinical trial for the new liposomal formulation (e7389-lf) of the in-house discovered anti-cancer treatment halaven® (generic name: eribulin mesylate, “eribulin”) were presented (abstract number: 346p) at the european society for medical oncology (esmo) virtual congress 2020.

eisai to present abstracts on oncology products and pipeline at esmo virtual congress 2020

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that a series of abstracts will be presented at the european society for medical oncology (esmo) virtual congress 2020 from september 19 to 21, 2020. the abstracts highlight updates regarding eisai’s in-house discovered lenvima® (lenvatinib mesylate, the orally available kinase inhibitor, “lenvatinib”), halaven® (eribulin mesylate, halichondrin class microtubule dynamics inhibitor, “eribulin”) and its liposomal formulation.

eisai to take over manufacturing and marketing approval for equfina® 50mg tablets (safinamide mesilate) in japan from meiji seika pharma

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it will take over by transfer the manufacturing and marketing approval of parkinson’s disease treatment equfina® 50mg tablets (safinamide mesilate, “equfina”) in japan from meiji seika pharma co., ltd. (headquarters: tokyo, “meiji”), effective september 23, 2020.

eisai china wins “greater suzhou best employer” award for four consecutive years

the 7th “award ceremony for 2020 greater suzhou best employer and employer brand forum” was grandly held in the studio of suzhou radio and television general station recently. eisai china inc. stood out among thousands of participating enterprises with its good employer brand image, excellent performance of employer social responsibilities and excellent employee engagement, and has been awarded the “greater suzhou best employer” award for four consecutive years.

promote development of core philosophy of eisai – the second hhc summit of eisai china

on september 1, 2020, the second hhc summit of eisai china holdings ltd. (hereinafter referred to as “eisai china”) was successfully held in shanghai. feng yanhui, senior vice president of eisai global, president of eisai china, and chairman of eisai china hhc committee, led the senior management team of eisai china and leaders of various departments to attend the summit. 

网站地图